Khoso Baluch

CIK: 0001686223

Transaction Breakdown

Open Market Buys (P)2 (20.0%)

High conviction signal

Open Market Sales (S)1 (10.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (70.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PCSA

Processa Pharmaceuticals, Inc.

Director

LGVN

Longeveron Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

PCSA
Processa Pharmaceuticals, Inc.
Jul 26, 2026
Award(A)
Restricted Stock Units
Direct
33.5K shares-
PCSA
Processa Pharmaceuticals, Inc.
Mar 31, 2026
Purchase(P)
Direct
2.3K shares at avg. $2.54$6K
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
100K shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Stock Options (Right to Buy)
Direct
300K shares-
LGVN
Longeveron Inc.
Aug 11, 2025
Purchase(P)
Direct
11.8K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jul 24, 2025
Award(A)
Restricted Stock
Direct
175.3K shares-
LGVN
Longeveron Inc.
Jul 15, 2025
Award(A)
Direct
17K shares-
LGVN
Longeveron Inc.
Dec 2, 2024
Sale(S)
Direct
1.3K shares at avg. $2.07$3K
PCSA
Processa Pharmaceuticals, Inc.
Sep 3, 2024
Award(A)
Restricted Stock
Direct
31.2K shares-
PCSA
Processa Pharmaceuticals, Inc.
Sep 3, 2024
Award(A)
Restricted Stock
Direct
31.2K shares-

		Type	Shares	Price		Ownership
Jul 26, 2026	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	33,500	-	-	Direct
Mar 31, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,269	$2.54	$5,752	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	100,000	-	-	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Stock Options (Right to Buy)	300,000	-	-	Direct
Aug 11, 2025	LGVN Longeveron Inc.	Purchase(P)	11,766	-	-	Direct
Jul 24, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock	175,299	-	-	Direct
Jul 15, 2025	LGVN Longeveron Inc.	Award(A)	17,000	-	-	Direct
Dec 2, 2024	LGVN Longeveron Inc.	Sale(S)	1,250	$2.07	$2,588	Direct
Sep 3, 2024	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock	31,206	-	-	Direct
Sep 3, 2024	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock	31,206	-	-	Direct

1-10 of 10 transactions

About Baluch Khoso

Baluch Khoso (SEC CIK 0001686223) files insider reports with the SEC as Director of Processa Pharmaceuticals, Inc. (PCSA) and Director of Longeveron Inc. (LGVN).

Signal8 holds 9 ownership filings by Baluch Khoso, all Form 4s, filed between Sep 18, 2024 and Jul 28, 2026. Those filings report 10 transactions, from Sep 3, 2024 to Jul 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Baluch Khoso's filings is in VERO BEACH, FL.

Recent filings by Baluch Khoso

Jul 26, 2026: Grant or award of PCSA derivative securities (Form 4, code A).
Mar 31, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Oct 1, 2025: Grants or awards of PCSA derivative securities (2 lines, Form 4, code A).
Aug 11, 2025: Open-market purchase of LGVN shares (Form 4, code P).
Jul 24, 2025: Grant or award of PCSA derivative securities (Form 4, code A).

Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)

Ng George K, Chief Executive Officer
GUJRATHI SHEILA, Director
Yorke Justin W, Director
SKIBSTED RUSSELL, Chief Financial Officer
Pannu Geraldine, Director
Neal James R, Director

How to read Form 4 transaction codes